Vanguard Portfolio Management
TBPH icon

Vanguard Portfolio Management’s Theravance Biopharma TBPH Stock Holding History

Vanguard Portfolio Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.7M Sell
394,158
-6,601
-2% -$109K ﹤0.01% 2341
2026
Q1 		$6.5M Buy
+400,759
New +$7.09M ﹤0.01% 2247

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management's TBPH Position: Q2 2026 in Review

Vanguard Portfolio Management reduced its Theravance Biopharma (TBPH) stake by 1.6% in Q2 2026, selling an estimated $109K and leaving 394,158 shares worth $6.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2341.

Vanguard Portfolio Management first reported a position in TBPH in Q1 2026 and has held it in 2 quarters since. 178 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Vanguard Portfolio Management held 394,158 shares of Theravance Biopharma worth $6.7M as of Q2 2026.
  • Vanguard Portfolio Management sold 6,601 Theravance Biopharma shares in Q2 2026, an estimated $109K.
  • Theravance Biopharma made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2341 holding.
  • Vanguard Portfolio Management first reported a position in Theravance Biopharma in Q1 2026 and has held it in 2 quarters since.
  • 178 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.